Comparative Effectiveness Research

🔍 Can comparative effectiveness research (CER) make drug pricing fairer and more evidence-driven? This article explains how integrating CER into pricing frameworks can align prices with real-world value, improve payer decision-making, and support sustainable access—while outlining practical policy and methodological steps to get there. Read the full piece to see actionable recommendations for policymakers, payers, and manufacturers. ➡️ #SyenzaNews #HealthEconomics #pharmaceuticals #MarketAccess #costeffectiveness

What if HTA decisions could be tracked in real time? 🔍📊 Infarmed’s new real-time Health Technology Assessment tracker brings greater transparency to appraisal timelines, evidence and outcomes. It gives manufacturers, payers and policymakers the data needed to anticipate market access, streamline submissions and improve planning. Read the full article to see how the tracker works and what it means for regulatory strategy and market access. #SyenzaNews #HealthTechnology #regulatoryaffairs #MarketAccess #DigitalTransformation

🌟 Are you ready for a transformation in pharmacoeconomic assessments? The Dutch National Health Care Institute is set to unveil its **Pharmacoeconomic Redesign** on September 1, 2025, introducing a refined framework for evaluating drug reimbursement in the Netherlands. This innovative approach emphasizes clarity, transparency, and methodological rigor, ensuring more informed decisions in healthcare. Dive into the article to discover how these changes will impact market access and elevate standards in health economics! #SyenzaNews #HealthEconomics #MarketAccess

🚀 The National Institute for Health and Care Excellence (NICE) has made great strides in 2024, reporting a record number of positive recommendations for blood cancer therapies. This pivotal moment not only accelerates patient access to advanced treatments but also highlights the importance of precision medicine in oncology care. Curious to learn how these advancements are reshaping the healthcare landscape and improving patient outcomes? Explore the full article for insights! #SyenzaNews #oncology #HealthcareInnovation

🔍 The conversation surrounding elacestrant for advanced breast cancer is gaining momentum! The National Institute for Health and Care Excellence (NICE) is working closely with Menarini Stemline to address critical uncertainties in evidence. As this drug aims to tackle oestrogen receptor-positive, HER2-negative breast cancers with activating ESR1 mutations, public consultation is underway until 22 October 2024. Stay informed about potential advancements in treatment options and the importance of collaboration in healthcare. #SyenzaNews #BreastCancer #HealthcareInnovation

🌟 Transforming Child Mental Health Services with Digital Interventions 🌟 Discover how digitally augmented therapies are bridging gaps in child mental health services, offering cost-effective solutions without compromising outcomes. Let's harness technology to improve access and efficiency in treating childhood anxiety. #SyenzaNews #MentalHealth #DigitalHealth #ChildHealth #Innovation 📢 Join the conversation: How can digital interventions reshape mental health care for children? Share your thoughts below! 👇

🌟 Discover how system dynamics modelling in mental health can transform planning in Australia! 🌟 Read our latest insights revealing the cost-effectiveness of key interventions and highlighting the benefits of using advanced modelling techniques. Let's make mental health systems more efficient and equitable. #SyenzaNews #MentalHealth #SystemDynamics #HealthcareInnovation #Australia

🌟 New Insights on Integrated Care for Children 🌟 This recent study evaluates the cost-effectiveness of the Children and Young People's Health Partnership (CYPHP) model for chronic conditions like asthma, eczema, and constipation. Discover how integrated care impacts health outcomes and societal costs. 📊 #SyenzaNews #ChronicConditions #IntegratedCare #Paediatrics #CostEffectiveness #HealthEconomics 👉

🌟 The role of biosimilars in Multiple Sclerosis treatment is expanding, offering more affordable and accessible options for patients. Learn how these biologic medications are transforming MS care by reducing costs and increasing treatment options. 🧬💊 #SyenzaNews #Biosimilars #MultipleSclerosis #HealthcareInnovation #PatientCare #MedicalResearch

🌟 Exciting News! Learn how specialised geriatric cancer rehabilitation programmes are transforming health outcomes for older adults undergoing cancer treatment. Discover the effect of personalised care and comprehensive assessments in enhancing quality of life. #SyenzaNews #GeriatricCancerRehabilitation #ElderlyCare #SeniorHealth #QualityofLife Discover how geriatric-specific cancer rehabilitation can provide significant improvements in emotional health, social connectedness, and independence for seniors undergoing cancer treatment. Let's work together to integrate these vital programs into oncology care pathways. 💪

🌟 #SyenzaNews: The landscape of Alzheimer's treatment is evolving with new drugs on the horizon. While NICE recently found lecanemab's benefits too small to justify its cost, promising treatments like donanemab, remternetug, and blarcamesine show potential. Learn more about these emerging therapies and their impact on Alzheimer's care. 💊🧠 #AlzheimersResearch #HealthcareInnovation #PharmaNews #DementiaCare

Thailand's healthcare system is a beacon of efficiency and effectiveness. Achieving Universal Health Coverage in 2002, the country has made remarkable strides in health outcomes, despite spending less compared to other upper-middle-income countries. Learn how Thailand's use of Health Technology Assessment (HTA) has played a crucial role in this success and the future steps to address current challenges. 🌍💉 #SyenzaNews #Healthcare #UniversalHealthCoverage #HTA #Innovation